Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Do not coadminister: decreased levels of lenacapavir
Drug 1
Drug 1 dose
300 mg orally x 1
Drug 1 effect
AUC decreased 55%; Cmax decreased 36%
Drug 2
Drug 2 dose
600 mg daily (fasted)
Drug 2 effect
Not reported
Mechanism
Induction of CYP3A4 and P-gp by efavirenz
Clinical Effects
Potential for loss of lenacapavir efficacy
Management
Use alternative agents
Info Source
